A research study of two immunotherapy drugs (derazantinib and atezolizumab) in patients with urothelial (bladder) cancer

UVA Tracking #
HSR190097
Principal Investigator
Michael Devitt
Contact
Jennifer Drake
Contact Email
Contact Phone
434.297.7782
Official Trial Title
An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)
Study Description

The UVA Cancer Center seeks adults ages 18 and over with urothelial (bladder) cancer for a clinical trial. The purpose of this study is to evaluate an investigative immunotherapy drug (derazantinib) alone or in combination with another immunotherapy drug (atezolizumab) in patients with urothelial cancer. Disease response and good and bad effects of the drug will be studied as part of this study. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04045613

Compensation

Compensation: $85 per visit. Reimbursement: Up to $175 for hotel stay.